论文部分内容阅读
目的通过研究白细胞介素2(IL2)基因转染联合特异性细胞毒T淋巴细胞(CTL)对人肝癌细胞(HepG2)的体外杀伤试验,探讨一种肝癌的免疫基因治疗方法。方法采用多聚阳离子脂质体作载体,将IL2基因转染至HepG2细胞,通过检测IL2浓度变化,观察转染效率。用MTT法检测其联合特异性CTL细胞对HepG2细胞的杀伤作用。结果转染IL2基因至HepG2细胞的体外最佳转染比例为5∶1,其可持续分泌IL230d,分泌高峰在转染后第2～3天。联合特异性CTL细胞,对HepG2细胞显示明显的协同杀伤效应。结论经转染IL2基因后,HepG2细胞分泌IL2可达30d,可以有效地维持特异性CTL细胞的活力,两者联合,对杀伤肝癌细胞有明显的协同效应。
OBJECTIVE: To study the immune gene therapy of hepatocellular carcinoma (HCC) in vitro by studying the cytotoxicity of interleukin 2 (IL2) gene combined with specific cytotoxic T lymphocytes (CTL) on HepG2 cells in vitro. Methods Polycationic liposomes were used as the carrier, IL2 gene was transfected into HepG2 cells, and the transfection efficiency was observed by detecting the concentration of IL2. The cytotoxicity of CTL cells to HepG2 cells was detected by MTT assay. Results The best transfection ratio of IL2 gene to HepG2 cells in vitro was 5: 1, which could be secreted IL230 continuously. The peak of secretion was at day 2 to 3 after transfection. Combination of specific CTL cells, HepG2 cells showed a significant synergistic killing effect. CONCLUSION: IL2 can be secreted by HepG2 cells for up to 30 days after transfection with IL2 gene, which can effectively maintain the activity of specific CTL cells. Combining the two results in a synergistic effect on killing hepatoma cells.